---
title: Alkylating Agents - Chemotherapy
type: content
phase: 1
status: complete
priority: high
tags: [chemotherapy, alkylating-agents, cyclophosphamide, platinum, cisplatin, carboplatin, oxaliplatin, nitrogen-mustards]
created: 2025-11-08
last_modified: 2025-11-08
---

# Alkylating Agents - Chemotherapy

## Introduction

Alkylating agents are among the oldest and most widely used chemotherapy drugs. They work by forming covalent bonds (alkylation) with DNA, leading to DNA damage and cell death. Understanding their mechanisms, clinical uses, and toxicities is essential for cancer treatment.

## Mechanism of Action

### General Mechanism

**Alkylation**:
- Transfer **alkyl groups** (e.g., CH3-CH2-) to nucleophilic sites on DNA
- **Guanine N7** position most common target
- **DNA cross-linking** (interstrand, intrastrand):
  - Prevents DNA strand separation
  - **Blocks DNA replication and transcription**
- **DNA breaks**, **miscoding**

**Cell Death**:
- DNA damage → cell cycle arrest → **apoptosis**
- **Cell cycle non-specific** (kill dividing and resting cells)
  - But more effective on rapidly dividing cells

**Resistance**:
- ↑DNA repair (e.g., O6-alkylguanine-DNA alkyltransferase)
- ↓Drug uptake
- ↑Glutathione (detoxification)

---

## Classification

### Nitrogen Mustards
- Cyclophosphamide, ifosfamide
- Mechlorethamine, melphalan, chlorambucil, bendamustine

### Platinum Compounds
- Cisplatin, carboplatin, oxaliplatin

### Nitrosoureas
- Carmustine (BCNU), lomustine (CCNU), streptozocin

### Alkyl Sulfonates
- Busulfan

### Triazenes
- Dacarbazine, temozolomide

### Other
- Procarbazine, altretamine

---

## Nitrogen Mustards

### Cyclophosphamide (Cytoxan)

**Mechanism**:
- **Prodrug** → activated by hepatic **CYP450** → phosphoramide mustard (active)
- DNA cross-linking

**Pharmacokinetics**:
- Oral, IV
- Hepatic activation required
- Renal excretion (active metabolites)

**Clinical Uses**:
1. **Lymphomas** (Hodgkin's, non-Hodgkin's)
2. **Breast cancer**
3. **Ovarian cancer**
4. **Lung cancer** (small cell)
5. **Autoimmune diseases**: Lupus nephritis, vasculitis (immunosuppression)
6. **Conditioning regimen** (bone marrow transplant)

**Dosing**: Variable (50-200 mg/m2 oral daily, or 500-1500 mg/m2 IV)

**Adverse Effects**:

**Myelosuppression**:
- **Dose-limiting**
- Nadir: 7-14 days

**Hemorrhagic Cystitis** (10-40%):
- **Acrolein** (toxic metabolite) damages bladder epithelium
- **Prevention**: **Mesna** (binds acrolein), hydration, frequent voiding
- Symptoms: Hematuria, dysuria

**SIADH** (Syndrome of Inappropriate ADH):
- ↑ADH secretion → hyponatremia
- Monitor sodium (especially high doses)

**Nausea/Vomiting**:
- Highly emetogenic (especially high doses)
- Antiemetics required

**Cardiotoxicity** (High Doses):
- Hemorrhagic myocarditis
- Pericardial effusion
- Risk >150-200 mg/kg cumulative

**Infertility**:
- Ovarian failure, azoospermia
- Dose-dependent, often permanent

**Secondary Malignancies**:
- Acute myeloid leukemia (AML)
- Bladder cancer (chronic cystitis)

**Clinical Pearls**:
- **Mesna essential** for high doses (prevents cystitis)
- **Hydration** (2-3 L/day)
- **Broad-spectrum** use (solid tumors, lymphomas, autoimmune)

### Ifosfamide

**Similar to cyclophosphamide**

**Differences**:
- **Higher hemorrhagic cystitis risk** (15-40%)
- **Neurotoxicity**: Encephalopathy, confusion, seizures (10-30%)
  - Methylene blue may help
- **Always use with Mesna**

**Clinical Uses**:
- Testicular cancer
- Sarcomas
- Lymphomas

### Mechlorethamine (Nitrogen Mustard)

**Historical**: First nitrogen mustard (WWII - mustard gas derivative)

**Clinical Uses**:
- **Hodgkin's lymphoma** (MOPP regimen - historical)
- **Topical**: Mycosis fungoides (cutaneous T-cell lymphoma)

**Adverse Effects**:
- **Severe vesicant** (IV extravasation → tissue necrosis)
- Myelosuppression, nausea

**Status**: Largely replaced by less toxic agents

### Melphalan

**Clinical Uses**:
- **Multiple myeloma**
- **Conditioning** for stem cell transplant
- Ovarian cancer

**Dosing**: Oral, IV (high-dose for transplant)

**Adverse Effects**:
- Myelosuppression (dose-limiting)
- Nausea, mucositis
- Secondary AML

### Chlorambucil

**Clinical Uses**:
- **Chronic lymphocytic leukemia (CLL)**
- Low-grade lymphomas

**Dosing**: Oral (outpatient, chronic)

**Adverse Effects**:
- Myelosuppression (delayed, prolonged)
- Secondary AML
- Generally well-tolerated

### Bendamustine

**Structure**: Hybrid (nitrogen mustard + purine analog)

**Clinical Uses**:
- **Chronic lymphocytic leukemia (CLL)**
- **Non-Hodgkin's lymphoma** (rituximab combination)
- Multiple myeloma

**Dosing**: IV infusion

**Adverse Effects**:
- Myelosuppression
- Infusion reactions
- Skin reactions (Stevens-Johnson syndrome - rare)
- Less nausea than other alkylators

**Clinical Pearl**: **Well-tolerated**, effective for hematologic malignancies

---

## Platinum Compounds

**Mechanism**: DNA cross-linking (platinum-DNA adducts)
- **Cisplatin**: Intrastrand cross-links (adjacent guanines)
- **Carboplatin**: Similar to cisplatin
- **Oxaliplatin**: Different DNA adducts (1,2-diaminocyclohexane)

### Cisplatin

**Mechanism**:
- **Platinum-DNA adducts** → intrastrand cross-links
- Prevents DNA replication, transcription
- Apoptosis

**Pharmacokinetics**:
- IV only
- **Requires hydration** (nephrotoxicity prevention)
- Platinum persists in tissues (long terminal half-life)

**Clinical Uses** (Broad-spectrum):
1. **Testicular cancer** (curative - BEP regimen)
2. **Ovarian cancer**
3. **Bladder cancer**
4. **Head and neck cancer**
5. **Lung cancer** (non-small cell, small cell)
6. **Cervical cancer**
7. **Esophageal, gastric cancer**

**Dosing**: 50-100 mg/m2 IV (with aggressive hydration)

**Adverse Effects**:

**Nephrotoxicity** (Dose-Limiting):
- **Acute tubular necrosis**
- **Prevention**:
  - **Aggressive IV hydration** (2-3 L saline before/after)
  - **Mannitol** or **furosemide** (forced diuresis)
  - **Amifostine** (cytoprotective - rarely used)
- **Monitor**: Creatinine, CrCl, Mg2+
- **Cumulative** toxicity

**Ototoxicity** (20-30%):
- **High-frequency hearing loss** (often irreversible)
- **Tinnitus**
- **Dose-related, cumulative**
- More common children
- **Baseline and serial audiograms**

**Peripheral Neuropathy** (30-100%):
- **Sensory** (stocking-glove)
- **Cumulative**, often irreversible
- **Dose-limiting** (with nephrotoxicity)

**Electrolyte Wasting**:
- **Hypomagnesemia** (common, renal Mg2+ wasting)
- Hypokalemia, hypocalcemia
- **Supplement Mg2+, K+**

**Nausea/Vomiting**:
- **Highly emetogenic** (most emetogenic chemo)
- **5-HT3 antagonists, NK1 antagonists, dexamethasone** required

**Myelosuppression**:
- Moderate (less than other alkylators)

**Anaphylaxis/Hypersensitivity** (Rare):
- More common after multiple cycles

**Cardiotoxicity** (Rare):
- Arrhythmias, ischemia

**Clinical Pearls**:
- **Aggressive hydration essential** (100-150 mL/hr before/after)
- **Monitor renal function, electrolytes** (Cr, Mg2+, K+)
- **Hearing loss cumulative** (audiograms)
- **Highly effective** (curative in testicular cancer)

### Carboplatin

**Relationship**: **Analog of cisplatin** (less reactive, better-tolerated)

**Advantages over Cisplatin**:
- **Less nephrotoxic** (no mandatory hydration)
- **Less emetogenic**
- **Less neurotoxic**
- **Less ototoxic**
- **Better-tolerated**

**Disadvantage**:
- **More myelosuppression** (dose-limiting)
  - **Thrombocytopenia** (nadir 14-21 days)

**Clinical Uses**: Similar to cisplatin (often substituted for better tolerability)
- Ovarian cancer (first-line)
- Lung cancer
- Head and neck cancer

**Dosing**:
- **AUC-based dosing** (Calvert formula):
  - Dose (mg) = AUC × (GFR + 25)
  - Typical AUC: 5-6

**Monitoring**: CBC (thrombocytopenia)

**Clinical Pearl**: **Preferred when nephrotoxicity concern** (elderly, renal impairment)

### Oxaliplatin

**Mechanism**: Similar platinum-DNA cross-linking (different adducts)

**Clinical Uses**:
1. **Colorectal cancer** (FOLFOX regimen - with 5-FU/leucovorin)
2. **Gastric, pancreatic cancer**

**Unique Toxicity**:

**Acute Cold-Induced Neuropathy**:
- **Laryngopharyngeal dysesthesia**: Throat/jaw tightness (cold-triggered)
- **Peripheral dysesthesia**: Tingling hands/feet (cold-triggered)
- **Onset within hours**, resolves in days
- **Avoid cold** (drinks, objects) for 3-5 days post-infusion

**Chronic Peripheral Neuropathy**:
- **Cumulative, dose-limiting**
- Sensory > motor
- May be **irreversible**
- Limit cumulative dose (<850 mg/m2)

**Other Adverse Effects**:
- Myelosuppression (moderate)
- Nausea/vomiting (moderate)
- Diarrhea (with 5-FU)
- Hypersensitivity reactions (infusion reactions - can be severe)

**Clinical Pearls**:
- **Warn patients about cold sensitivity** (acute neuropathy)
- **Neuropathy dose-limiting** (cumulative)
- **Standard for colorectal cancer** (FOLFOX)

---

## Nitrosoureas

**Mechanism**: DNA and RNA alkylation, carbamylation of proteins

**Unique Property**: **Lipophilic** → **cross blood-brain barrier**

### Carmustine (BCNU)

**Clinical Uses**:
- **Brain tumors** (glioblastoma)
- **Lymphomas**
- **Gliadel wafer** (implantable - direct CNS delivery)

**Adverse Effects**:
- **Myelosuppression** (delayed, cumulative - nadir 4-6 weeks)
- **Pulmonary fibrosis** (dose-limiting, cumulative >1400 mg/m2)
- Hepatotoxicity
- Nausea

### Lomustine (CCNU)

**Clinical Uses**: Brain tumors

**Adverse Effects**: Similar to carmustine

### Streptozocin

**Unique**: Selective for **pancreatic islet cells** (glucose transporter uptake)

**Clinical Uses**:
- **Pancreatic neuroendocrine tumors** (islet cell tumors)

**Adverse Effects**:
- **Nephrotoxicity** (cumulative)
- **Hypoglycemia** (β-cell destruction)
- Minimal myelosuppression

---

## Other Alkylating Agents

### Busulfan

**Clinical Uses**:
- **Chronic myeloid leukemia (CML)** (historical)
- **Conditioning regimen** (stem cell transplant)

**Adverse Effects**:
- **Pulmonary fibrosis** ("busulfan lung")
- **Seizures** (high-dose) - prophylactic anticonvulsants
- Hyperpigmentation
- Hepatic sinusoidal obstruction syndrome (SOS/VOD)

### Dacarbazine

**Clinical Uses**:
- **Melanoma**
- **Hodgkin's lymphoma** (ABVD regimen)
- Sarcomas

**Mechanism**: Prodrug → MTIC (active)

**Adverse Effects**:
- Nausea/vomiting (severe)
- Myelosuppression
- Flu-like syndrome

### Temozolomide

**Relationship**: Oral analog of dacarbazine

**Clinical Uses**:
- **Glioblastoma** (first-line with radiation)
- Anaplastic astrocytoma
- Melanoma

**Advantages**:
- **Oral** (convenient)
- **Crosses BBB**
- **Better-tolerated** than dacarbazine

**Adverse Effects**:
- Myelosuppression (especially thrombocytopenia)
- Nausea
- Pneumocystis jirovecii pneumonia (PCP) risk - **prophylaxis** (TMP-SMX)

**Clinical Pearl**: **Standard for glioblastoma** (with radiation, then maintenance)

### Procarbazine

**Clinical Uses**:
- **Hodgkin's lymphoma** (BEACOPP regimen)
- Brain tumors

**Mechanism**: Multiple (alkylation, free radicals, MAO inhibition)

**Adverse Effects**:
- Myelosuppression
- Nausea
- **MAO inhibitor effects**:
  - **Tyramine reaction** (avoid aged cheese, wine)
  - **Drug interactions** (SSRIs, sympathomimetics)
- Disulfiram-like reaction (alcohol)

**Clinical Pearl**: **Avoid tyramine-rich foods** (cheese, wine)

---

## General Adverse Effects (All Alkylating Agents)

### Common to Class

**Myelosuppression**:
- Dose-limiting for most
- Nadir varies (7-14 days typical, 4-6 weeks nitrosoureas)

**Nausea/Vomiting**:
- Variable severity (cisplatin most emetogenic)

**Infertility**:
- Ovarian failure, azoospermia
- Often irreversible
- **Fertility preservation** counseling before treatment

**Secondary Malignancies**:
- **Acute myeloid leukemia (AML)** - classic association
- **Myelodysplastic syndrome (MDS)**
- Latency: 5-10 years
- Risk: 1-2% (cumulative with dose, duration)

**Mutagenicity, Teratogenicity**:
- Avoid pregnancy during treatment

---

## Supportive Care

**Mesna** (Cyclophosphamide, Ifosfamide):
- **Binds acrolein** in urine
- **Prevents hemorrhagic cystitis**
- Dose: 60-100% of chemotherapy dose (divided)

**Hydration** (Cisplatin):
- **2-3 L saline** pre/post-infusion
- Mannitol/furosemide diuresis

**Antiemetics** (All):
- 5-HT3 antagonists (ondansetron, granisetron)
- NK1 antagonists (aprepitant) - highly emetogenic
- Dexamethasone
- Olanzapine

**Growth Factors** (Myelosuppression):
- G-CSF (filgrastim) for neutropenia
- Erythropoietin (rarely)

**Electrolyte Replacement** (Cisplatin):
- Magnesium, potassium supplementation

---

## Clinical Pearls

1. **Alkylating agents** form DNA cross-links → apoptosis
2. **Cell cycle non-specific** but preferentially kill dividing cells
3. **Cyclophosphamide**: Broad use (lymphomas, breast, autoimmune), mesna for cystitis prevention
4. **Cisplatin**: Highly effective (testicular cancer curative), nephrotoxic (hydration required), ototoxic
5. **Carboplatin**: Better-tolerated than cisplatin (less nephro/oto toxic), more myelosuppression
6. **Oxaliplatin**: Colorectal cancer (FOLFOX), acute cold-induced neuropathy (warn patients)
7. **Nitrosoureas cross BBB** (brain tumors)
8. **Temozolomide**: Oral, glioblastoma standard, PCP prophylaxis
9. **Secondary AML/MDS** risk with all alkylators (5-10 years latency)
10. **Mesna essential** for cyclophosphamide/ifosfamide (prevents cystitis)

---

## Key Takeaways

1. **Mechanism**: Alkylate DNA (guanine N7) → cross-links → apoptosis
2. **Cell cycle non-specific**: Kill dividing and resting cells
3. **Cyclophosphamide**: Prodrug, lymphomas/breast/autoimmune, hemorrhagic cystitis (mesna prevention)
4. **Cisplatin**: Platinum, testicular/ovarian/bladder cancer, nephrotoxic (hydration), ototoxic
5. **Carboplatin**: Better-tolerated cisplatin analog, more myelosuppression
6. **Oxaliplatin**: Colorectal cancer, acute cold neuropathy, chronic neuropathy cumulative
7. **Nitrosoureas**: Lipophilic (cross BBB), brain tumors, delayed myelosuppression
8. **Common toxicities**: Myelosuppression, nausea, infertility, secondary AML
9. **Supportive care**: Mesna (cystitis), hydration (nephrotoxicity), antiemetics
10. **Resistance**: ↑DNA repair, ↓uptake, ↑glutathione

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition
4. NCCN Clinical Practice Guidelines in Oncology
5. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990.
